ADC Is Beneficial for Survival in Mets Cervical Cancer.

Published Date: 04 Nov 2023

When used in conjunction with chemotherapy as a second or third line treatment for recurrent or metastatic cervical cancer, the antibody-drug conjugate tisotumab vedotin produced better results.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

Glioblastoma treatment breakthrough shows promise

3.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

4.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot